Posted by Michael Wonder on 17 May 2023
Lumen Bioscience receives fast track designation from US FDA for LMN-201
17 May 2023 - Orally delivered biologic drug for treatment and prevention of C. difficile infection.
Lumen Bioscience today announced that the US FDA has granted fast track designation for LMN-201, an investigational, orally delivered biologic drug to treat and prevent C. difficile infection.
